AIM
SPRY icon

Aigen Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

Aigen Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,515
Closed -$216K – 1012
2024
Q4 		$216K Buy
+20,515
New +$287K 0.04% 590

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Aigen Investment Management's SPRY Position: Q1 2025 in Review

Aigen Investment Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 20,515 shares — an estimated $216K sold.

Aigen Investment Management first reported a position in SPRY in Q4 2024 and held it in 1 quarter. The position peaked at $216K in Q4 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Aigen Investment Management reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Aigen Investment Management sold 20,515 ARS Pharmaceuticals shares in Q1 2025, an estimated $216K.
  • Aigen Investment Management first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Aigen Investment Management's ARS Pharmaceuticals position peaked at $216K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.